Greenwich Investment Management, Inc. Abb Vie Inc. Transaction History

Greenwich Investment Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 16, 2023	BUY	$133.59 - $154.65 $194,640 - $225,325	1,457 New	1,457 $217,000
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $57,398 - $68,836	-415 Reduced 22.17%	1,457 $235,000
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $134,210 - $153,930	-1,000 Reduced 34.82%	1,872 $251,000
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $7,918 - $9,825	-60 Reduced 2.05%	2,872 $466,000
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $6,445 - $8,155	60 Added 2.09%	2,932 $397,000
Q1 2020 May 12, 2020	SELL	$64.5 - $97.79 $3,225 - $4,889	-50 Reduced 1.71%	2,872 $219,000
Q4 2019 Feb 07, 2020	BUY	$72.13 - $90.25 $210,763 - $263,710	2,922 New	2,922 $259,000
Q1 2019 May 13, 2019	SELL	$77.14 - $90.79 $173,256 - $203,914	-2,246 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $201,151 - $220,579	2,246	2,246 $217,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Greenwich Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Greenwich Investment Management, Inc. with notifications on news.